List of Dapzura Rt drug patents

Dapzura Rt is owned by Baxter Hlthcare Corp.

Dapzura Rt contains Daptomycin.

Dapzura Rt has a total of 1 drug patent out of which 0 drug patents have expired.

Dapzura Rt was authorised for market use on 25 January, 2022.

Dapzura Rt is available in powder;intravenous dosage forms.

Dapzura Rt can be used as method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol.

The generics of Dapzura Rt are possible to be released after 11 March, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189 BAXTER HLTHCARE CORP Daptomycin formulations containing a combination of sorbitol and mannitol
Mar, 2041

(18 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 25 January, 2022

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in